An Vandebosch

4.1k total citations
24 papers, 661 citations indexed

About

An Vandebosch is a scholar working on Infectious Diseases, Statistics and Probability and Surgery. According to data from OpenAlex, An Vandebosch has authored 24 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 6 papers in Statistics and Probability and 4 papers in Surgery. Recurrent topics in An Vandebosch's work include Advanced Causal Inference Techniques (6 papers), Statistical Methods in Clinical Trials (4 papers) and COVID-19 epidemiological studies (3 papers). An Vandebosch is often cited by papers focused on Advanced Causal Inference Techniques (6 papers), Statistical Methods in Clinical Trials (4 papers) and COVID-19 epidemiological studies (3 papers). An Vandebosch collaborates with scholars based in Belgium, United States and United Kingdom. An Vandebosch's co-authors include Damayanthi Devineni, Donna Skee, Joseph Murphy, Marcus Hompesch, Sherwyn Schwartz, Linda Morrow, Kirk Ways, Steven Van Gucht, Eric Cox and Peter Meerts and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and Statistics in Medicine.

In The Last Decade

An Vandebosch

24 papers receiving 637 citations

Peers

Countries citing papers authored by An Vandebosch

Since Specialization

Citations

This map shows the geographic impact of An Vandebosch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by An Vandebosch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites An Vandebosch more than expected).

Fields of papers citing papers by An Vandebosch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by An Vandebosch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by An Vandebosch. The network helps show where An Vandebosch may publish in the future.

Co-authorship network of co-authors of An Vandebosch

This figure shows the co-authorship network connecting the top 25 collaborators of An Vandebosch. A scholar is included among the top collaborators of An Vandebosch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with An Vandebosch. An Vandebosch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjusting for Time-Varying Treatment Switches in Randomized Clinical Trials: The Danger of Extrapolation and How to Address It 2023 ·Statistics in Biopharmaceutical Research ·(unknown), An Vandebosch, Stijn Vansteelandt	2
2	Estimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials 2022 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), An Vandebosch, Stijn Vansteelandt	1
3	Improving interim decisions in randomized trials by exploiting information on short‐term endpoints and prognostic baseline covariates 2020 ·Pharmaceutical Statistics ·(unknown), An Vandebosch, Stijn Vansteelandt	13
4	Evaluating futility of a binary clinical endpoint using early read‐outs 2019 ·Statistics in Medicine ·(unknown), An Vandebosch, Stijn Vansteelandt, Filip De Ridder	6
5	Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial 2018 ·PLoS ONE ·Paul Meyvisch, (unknown), Koen Andries, Nacer Lounis, (unknown), Brian Dannemann, An Vandebosch, Wim Van der Elst, Geert Molenberghs, Ariel Alonso	10
6	Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection 2017 ·BMC Gastroenterology ·Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M. Schattenberg, Peter Buggisch, Sven Francque, Leen Vijgen, Thomas N. Kakuda, (unknown), Donghan Luo, An Vandebosch, (unknown), P. Van Remoortere, René Verloes	4
7	Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845 2017 ·Virology Journal ·Leen Vijgen, Kim Thys, An Vandebosch, P. Van Remoortere, René Verloes, Sandra De Meyer	4
8	Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone 2016 ·Vaccine ·Anton Camacho, Rosalind M. Eggo, Nele Goeyvaerts, An Vandebosch, Robin Mogg, Sebastian Funk, Adam J. Kucharski, Conall Watson, Tony Vangeneugden, W. John Edmunds	18
9	Simulation-guided phase 3 trial design to evaluate vaccine effectiveness to prevent Ebola virus disease infection: Statistical considerations, design rationale, and challenges 2016 ·Clinical Trials ·An Vandebosch, Robin Mogg, Nele Goeyvaerts, Carla Truyers, Brian Greenwood, (unknown), (unknown), Wim Parys, Tony Vangeneugden	7
10	Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor 2015 ·Clinical Therapeutics ·Damayanthi Devineni, Christopher R. Curtin, Thomas Marbury, William B. Smith, Nicole Vaccaro, David Wexler, An Vandebosch, Sarah Rusch, Hans Stieltjes, Ewa Wajs	39
11	A single‐dose, open‐label, parallel, randomized, dose‐proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia 2014 ·The Journal of Clinical Pharmacology ·Adriaan Cleton, Stefaan Rossenu, Herta Crauwels, Joris Berwaerts, David Hough, Srihari Gopal, Mariëlle Eerdekens, An Vandebosch, Bart Remmerie, Marc De Meulder, (unknown)	39
12	Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia 2014 ·Clinical Pharmacology in Drug Development ·Stefaan Rossenu, Adriaan Cleton, David Hough, Herta Crauwels, An Vandebosch, Joris Berwaerts, Mariëlle Eerdekens, Virginie M.M. Herben, Marc De Meulder, Bart Remmerie, Igor Francetić	22
13	Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants 2014 ·Clinical Pharmacology in Drug Development ·Damayanthi Devineni, Prasarn Manitpisitkul, Joseph Murphy, Donna Skee, Ewa Wajs, Rao N. V. S. Mamidi, Hong Tian, An Vandebosch, Shean‐Sheng Wang, Tom Verhaeghe, Hans Stieltjes, Keith Usiskin	18
14	Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin 2012 ·Diabetes Obesity and Metabolism ·Damayanthi Devineni, Linda Morrow, Marcus Hompesch, Donna Skee, An Vandebosch, Joseph Murphy, Kirk Ways, Sherwyn Schwartz	192
15	Pharmacokinetics of Dapoxetine Hydrochloride in Healthy Chinese, Japanese, and Caucasian Men 2010 ·The Journal of Clinical Pharmacology ·(unknown), Om P. Sharma, Tianmei Si, Joseph W. Aquilina, An Vandebosch, Shean‐Sheng Wang, (unknown), (unknown)	17
16	Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals 2010 ·International Clinical Psychopharmacology ·David Hough, Jaya Natarajan, An Vandebosch, (unknown), Michelle Kramer, Mariëlle Eerdekens	27
17	Correlation Between Type of Adaptive Immune Response Against Porcine Circovirus Type 2 and Level of Virus Replication 2005 ·Viral Immunology ·Peter Meerts, Steven Van Gucht, Eric Cox, An Vandebosch, Hans Nauwynck	111
18	Causal Proportional Hazards Models and Time-constant Exposure in Randomized Clinical Trials 2005 ·Lifetime Data Analysis ·Tom Loeys, Els Goetghebeur, An Vandebosch	11
19	Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities 2004 ·Sexually Transmitted Infections ·An Vandebosch	26
20	Structural accelerated failure time models for the effects of observed exposures on repeated events in a clinical trial 2004 ·Statistics in Medicine ·An Vandebosch, Els Goetghebeur, Lut Van Damme	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact